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Group A beta hemolytic streptococcus (GAS), the organism which initiates rheumatic fever
(RF) continues to be sensitive to penicillin. However, penicillin cannot prevent RF if the
preceding sore throat is asymptomatic in more than 70 percent children. Prevention of
rheumatic fever (RF) may be possible only with the use of a vaccine. Efforts to design a
vaccine based on emm gene identification of GAS, M-protein going on for more than 40
years, is unlikely to succeed. M-protein is strain specific. Infection with one strain does not
provide immunity from infection with another strain. Based on the emm gene identifica-
tion, of 250 or more identified strains of GAS, the distribution is heterogenous and keeps
changing. The M-protein gene sequence of the organism tends to mutate. A vaccine pre-
pared from available strains may not be effective against a strain following mutation.
Lethal toxic shock syndrome due to GAS infection has been described with organisms
without identifiable or functional M-protein. M-protein has been excluded as the antigen
responsible for acute glomerulonephritis (GN). Therefore M-protein plays no role in one
suppurative (toxic shock syndrome) and one non-suppurative (acute GN) manifestation
due to GAS infection. Lastly there is no direct evidence to indicate that M-protein is
involved in inducing RF. The role of M-protein and the GAS component resulting in the
suppurative manifestations of GAS infections like pyoderma, septic arthritis or necrotizing
fasciitis etc is unknown. For a vaccine to be effective, an epitope of the streptococcus which
is stable and uniformly present in all strains, needs to be identified and tested for its safety
and efficacy. The vaccine if and when available is expected to prevent GAS infection.
Preventing GAS infection will prevent all the suppurative as well as non-suppurative
manifestations including RF.
Copyright ª 2013, Cardiological Society of India. All rights reserved.It is generally accepted that rheumatic fever (RF) follows group
A beta hemolytic streptococcal (GAS) infection. Since GAS
infection spreads through droplets, overcrowding causes an
increased transmission from person to person. Undernutri-
tion or malnutrition can increase the susceptibility to infec-
tion. Poor socio-economic status results in an inability to3027.
.
2013, Cardiological Socieobtain optimal medical care. Hence a higher prevalence in
developing countries is predominantly related to low socio-
economic status. The resurgence of RF in the Utah area in
USA occurred in middle class families with a healthy lifestyle
without overcrowding, a suburban population with facilities
for good medical care indicates that improvement in socio-ty of India. All rights reserved.
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related to its capacity to causemore or less permanent cardiac
damage. In Utah epidemic, carditis based on clinical combined
with echocardiogram findings, occurred in almost 90 percent
patients.1 Hence prevention of rheumatic heart disease re-
quires preventing RF. The purpose of this communication is to
indicate that it is unlikely that a vaccine based on M-protein
will succeed in preventing RF. Prevention of RF can be
considered under two approaches e primary prevention and
secondary prevention.1. Secondary prevention
Secondary prevention consists in giving injections of intra-
muscular benzathine penicillin every two to three weeks
depending on age and muscle mass to patients who have
suffered from acute RF to prevent recurrences. Children
weighing more than 20 kg can be given 1,200,000 units of
benzathine penicillin every three weeks whereas younger
children weighing less than 20 kg can be given 600,000 units
every two weeks, since they do not have enoughmuscle mass
for the higher dose. Secondary prophylaxis is ethically
mandatory. If given properly, it reduces overall heart damage
from subsequent attacks and in some patients disappearance
of the auscultatory findings of valvar damage. However, sec-
ondary prophylaxis cannot reduce the burden of disease.
Disappearance of murmurs does not mean that the heart has
become normal. Recurrences bring out the former damage
and increase the cardiac damage further.2. Primary prevention
Primary prophylaxis consists in identifying that the patient
has a sore throat, that it is GAS infection and giving penicillin
to eradicate the GAS infection. Primary prophylaxis has too
many loopholes and is almost impossible to practice even for
individual patients. Resurgence of RF in USA indicates that
GAS sore throat was asymptomatic in 22e71 percent patients;
18 percent with sore throat asked for medical treatment; one
third to one half of acute RF occurred in asymptomatic pa-
tients and a 10 day oral penicillin course failed to protect the
patients from acute RF in 15e48 percent cases.1,2 Thus pri-
mary prevention is impossible if patients (parents) do not seek
medical help, do not complete the treatment course and if the
prescribed oral penicillin fails to prevent RF. As such, a 10 day
intramuscular penicillin course is mandatory if we want to
prevent RF. Intramuscular penicillin is painful, and is known
to give rise to anaphylactic reactions, even causing death (very
rarely). Many physicians refuse to give injectable penicillin
and in some parts of India, injectable penicillin is officially
banned.3. Vaccine
Primary prophylaxis is possible if an anti-GAS vaccine be-
comes available. Although a number of components of GAS
organism are being studied in order to make a vaccine, themost common andmaximum effort has been directed toward
an M-protein based vaccine. The specific role of streptococcal
M-protein in the pathogenesis of RF is not clear. Lancefield
isolated M-protein and designated it as the virulence factor of
GAS.3,4 M-protein has been extensively studied.5 It has ther-
mal stability, anti-phagocytic properties, capacity to initiate
immunological response and has a structural similarity to
tropomyosin. The M-protein, however, is strain specific and
produces type specific antibody response. This results in each
strain with its own specific M-protein failing to provide cross
immunity from infection by another strain. As of today, ac-
cording to the M-protein based classification, 250 strains of
GAS organism are known.6 M-protein has an alpha helical
coiled coil structure, similar to myosin and tropomyosin.7,8
Molecular mimicry between these proteins result in cross
reactive antibodies. It is likely that because of similarities in
the coiled coil structure of host proteins and streptococcal M-
protein a rise in titer of a variety of auto-antibodies against
these proteins is elicited in RF. Antibodies against a wide array
of antigens of cardiac, nuclear and streptococcal origin are
present in RF.9,10 The presence of antimyosin antibodies is not
indicative of cardiac muscle damage. Myosin specific anti-
bodies are present in polymyositis, cocksackie B myocarditis
and in patients following cardiac operations.11,12 A multiva-
lent vaccine based on hypervariable amino (N) terminal pep-
tides of M-protein from 26 emm classified strains of GAS from
Europe and USA has been utilized in clinical trials.13 Subse-
quently a 30 valent M-protein peptide based vaccine has been
evaluated.14 It produced bactericidal antibodies against all the
serotypes of GAS in the vaccine. In addition the vaccine pro-
duced antibodies against 24 of the 40 non vaccine GAS strains
indicating a wider utility. However, with more than 250
identified strains of GAS it is unlikely to be effective globally
not only because of the heterogeneity of GAS emm strain
distribution but also because of the capacity to mutate.15 The
reasons why efforts for the M-protein based vaccine, going on
for more than 40 years, are unlikely to succeed are outlined
below.
 Emm gene typing for all the GAS strains isolated from
children with sore throat in North India (Chandigarh) and
South India (Vellore) was performed.16 Of the 71 isolates of
GAS in North India 14 emm types were found. Of the 227
isolates of GAS in South India 59 emm types were found.
Comparing the isolates from North and South, only emm
type 11 was common to both places. The GAS emm types
varied from school to school and from one village to
another both in North and South India. In North India two
surveys were conducted three years apart. The GAS strains
circulating in the community were entirely different in the
two surveys (un-published data). Since immunity to GAS
M-protein is strain specific, it is obvious that a polyvalent
vaccine against most common isolates circulating in North
Indiawould be useless in South India or even inNorth India
three years later.
 Studies of Kaplan and associates in a semi-closed com-
munity indicate that rapid changes occur in the serotypes
causing infections and “broad non type specific immunity”
does not occur.17 Infection of GAS M1, strain may be fol-
lowed by M6 strain within 4.3e27.7 weeks even in a semi-
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protect against infection by M6 even within a short period.
Mutations occur in the emm gene sequence frequently. Six
out of 106 M6 strains found in the study differed in the
emm gene sequence from those in the data bank of the
WHO streptococcal reference lab. The authors stated that
“data also raise an important point regarding vaccine
effectiveness for candidate group A streptococcal vaccine
that are to be directed either towards conserved epitopes of
the M-protein or extracellular products of the organism”.8
Mutation will result in the vaccine becoming ineffective
against infection by the mutated organism.
 During the recent resurgence of RF in USA, heavily
encapsulated M18 and M3 strains which produced mucoid
colonies were found.18 In the intermountain area the
mucoid colonies of the strain did not result in a more se-
vere pharyngitis. The change in colony character and the
fact that RF resurgence occurred at the same time indicates
that a change in the organism had occurred.2 The change
resulted in its developing a capsule, grow asmucoid colony
and become virulent to result in RF. Krishna Kumar et al
discussing the epidemiology of streptococcal infection
state that “It is probable that the rheumatogenicity of
certain serotypes of streptococci is due to the clonal
emergence of a more virulent strain, by the acquisition of
virulence genes . A waxing and waning of normal ‘back-
ground’ group A streptococcal infections occurs with one
serotype becoming prevalent in a given population. A
virulent clone of this specific serotype may ‘emerge’
resulting in an epidemic”.19
 Bennett-Wood and associates have described toxic shock
syndrome, secondary to GAS infection in two unrelated
children from Australia.20 One child died of toxic shock
syndrome. GAS were isolated from the blood culture in
both children. The two isolated GAS strains did not express
M-protein. Electron microscopy could not identify M-pro-
tein fibrils on the surface of the organism which failed to
resist phagocytosis suggesting the absence of “functional
M-protein20”. The inference of the study would be that the
toxic shock syndrome e even lethal e could not be related
to M-protein, since M-protein was not involved. The viru-
lence must be due to some other component of the GAS
organism and M-protein cannot be the only virulence fac-
tor of the GAS organism.
 GAS infection results in two non-suppurative clinical
manifestationseacute RF and acute glomerulonephritis
(GN). Logically similarities should be present in the path-
ogenesis of the two immunologicalmanifestations. Studies
in acute GN have excluded M-protein as the antigen
responsible for the disease.21
 Rheumatic carditis was believed to result in myocarditis
andmyosin damage.M-protein designated as the virulence
factor of GAS was chosen as being responsible for myosin
damage because of its structural similarity to myosin. At
present we know that RF does not cause myocarditis or
myosin damage.22 Hence, utility of M-protein which tar-
gets myosin to formulate anti-GAS vaccine does not seem
to be justified. Despite all the studies, at present, there is no
evidence in the literature to indicate that M-protein is the
GAS antigen responsible for inducing RF.3.1. Comments
GAS infection results in two non-suppurative manifestations,
acute RF and acute GN as well as a number of suppurative
manifestations like toxic shock syndrome, necrotizing fascii-
tis, pyoderma, septic arthritis and others. Preventing GAS
infection should help prevent both types of manifestations.
The evaluation of findings related toM-protein indicate that:
 M-protein is strain specific. Infection from one strain does
not provide immunity for infection fromanother strain even
in a short period of four to six weeks. Since there are 250
strains, a polyvalent vaccine based on emm gene classifica-
tionofM-proteinswouldbeverydifficult toachieve,whether
conservedornonconservedareasofM-proteinareutilized.1,6
 On the basis of emm gene classification, the distribution of
GAS strains in the community is so variable and heterog-
enous that a polyvalent vaccine fromone areawill not be of
value in another area (North and South India) or even in the
same area sometime later.16
 Mutation in GAS emm gene occurs frequently enough that
themutated strainmay be able to result in RF despite being
a component (in the non mutated state) of a polyvalent
vaccine because of altered gene structure.17
 Absence of expressed M-protein in a lethal GAS organism
indicates that it cannot be the main or the only virulence
factor of the GAS organism.20
 M-protein has been excluded as the causative antigen for
acute GN, the other immunological manifestation of GAS
infection.21 At present there is no direct evidence that M-
protein is the antigen causing RF.
The questions which need to be answered are:
(i) why is it necessary to start from RF and its relation with
GAS M-protein in trying to make a vaccine ?
(ii) what is the role of M-protein in causing pyoderma or
other suppurative diseases?
(iii) why are we not looking for the virulent epitope of GAS
from infections causing toxic shock, pyoderma or septic
arthritis for its suitability for anti-GAS vaccine ?
If GAS infection can be prevented by a vaccine designed
fromorganisms causing arthritis, sepsis or pyoderma, it should
be good enough to prevent all GAS related disease manifesta-
tions.M-protein is not involved in thepathogenesis of acuteGN
theothernon-suppurativemanifestationofGAS infection. GAS
infection has resulted in death from toxic shock syndrome in
theabsenceofM-proteinbeingpresent,orexpressed.Therefore
acute GN a non-suppurative manifestation and toxics shock
syndromea suppurativemanifestationmaynot bepreventable
by a vaccine based on M-protein. It is necessary to look for an
epitope for vaccine which resulted in the death of a child from
toxic shock syndromedue toGAS infectionwithout identifiable
or functionalM-protein. The approach usingM-protein has not
provided the necessary break through in more than 40 years.
In order to make a vaccine, an attempt has to be made to
identify a component with immuno-reactive properties which
is uniformly present in all the GAS strains; does not alter or
retains its specificity even after mutation. A second possibility
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reclassified utilizing one or more features like e cell wall/
membrane protein, glycoprotein, streptococcal polysaccharide
etc. into groups with identical features, thus reducing the
requirement of the numbers of strains for making a vaccine.
A polyvalent vaccine based on emm gene identification of
more than 250 M-protein strains, which result in strain spe-
cific immunity; do not provide immunity against another
strain even for a few weeks, have a heterogenous distribution
in the community; keep mutating with time with themutated
strain may be having capacity to cause infection and disease
in spite of being a component (in non mutated state) in the
vaccine, is unlikely to succeed.
If a vaccine can prevent GAS infection it will prevent all the
clinical manifestations of GAS infection. Preventing disability
from RF or death from toxic shock syndrome from a vaccine
designed to prevent pyoderma from GAS infection will be a
tremendous achievement.4. Conclusions
Primary prevention of RF is possible only with a vaccine.
Injectable penicillin can prevent RF, however, it may not be
possible toprotect evenan individual fromRFutilizingpenicillin
if theantecedentsorethroat isasymptomatic.Sinceemmtyping
has resulted in the identification of 250 strains, each providing
specific individual immunity, utilizingM-protein as the basis of
ananti-GASvaccine isunlikely to succeed.Atpresent there isno
evidence to indicate that M-protein is responsible for RF. It has
already been excluded as a cause of acute GN, the other non-
suppurative manifestation of GAS infection. An attempt needs
to be made to identify an epitope of GAS organism which is
present, uniformly in all strains, is stable in spite of mutation
and can be utilized for making a vaccine.Conflicts of interest
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